QUOTE AND NEWS
TechCrunch  Oct 22  Comment 
 The crowdfunded fitness tracker Moov, built by former Apple engineer and HALO game designer Nikola Hu, Microsoft Research vets Meng Li (now Moov CEO) and Tony Yuan, has raised $3 million in new funding in a Series A round led by Banyan Capital....
StreetInsider.com  Oct 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Halozyme+Therapeutics+%28HALO%29+Receives+U.S.+Patent+%27034+Covering+PEGPH20-Related+Treatment/9891827.html for the full story.
StreetInsider.com  Oct 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/UPDATE%3A+Halozyme%27s+%28HALO%29+PEGPH20+Granted+FDA+Orphan+Designation+as+Pancreatic+Cancer+Treatment/9882811.html for the full story.
StreetInsider.com  Oct 2  Comment 
Resources Connection (NASDAQ: RECN) 5.9% HIGHER ; reported Q1 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $143.4 million versus the consensus estimate of $140.54 million. Halozyme...
StreetInsider.com  Sep 18  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Halozyme+Therapeutics+%28HALO%29+Reports+Removal+of+FDA+Clinical+Hold+on+PEGPH20+Phase+1b2/9843773.html for the full story.
Benzinga  Sep 18  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial (S1313). The trial is...
SeekingAlpha  Sep 16  Comment 
By Samreen Agha: The shares of Halozyme Therapeutics, Inc. (HALO) were up almost 7.5% afterhours following the news of FDA's approval of Halozyme and Baxter International's (BAX) HyQvia, on September 13, 2014. Come Monday the shares came tumbling...
SeekingAlpha  Sep 15  Comment 
By Emerging Equities: Halozyme Therapeutics Inc. (NASDAQ:HALO) recently announced that the FDA granted a Fast Track Designation for its PEGPH20 program in metastatic pancreatic cancer. It is still too early to speculate on a potential approval,...
FierceBiotech  Sep 15  Comment 
Two years after safety concerns torpedoed their first pitch, partners Baxter and Halozyme Therapeutics have locked up FDA approval for HyQvia, a treatment for immunodeficiency.
StreetInsider.com  Sep 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/FDA+Approves+Baxter%E2%80%99s+HYQVIA+for+Primary+Immunodeficiency+%28BAX%29+%28HALO%29/9830700.html for the full story.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki